Published in Clinical Trials Week, June 22nd, 2006
"We postulated that in type 2 diabetes, the postprandial phase is a proinflammatory state that can be modulated by PPAR-gamma agonists. For this purpose, we determined the effects of rosiglitazone (8 mg/d) on postprandial leukocyte counts and proinflammatory cytokines (IL-6 and IL-8) in patients with type 2 diabetes," scientists in Netherlands report.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.